Pluri (PLUR) risk factors
Item 1A of every Pluri Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors47 risks4 new4 dropped12 reworded
Nasdaq MVLS noncompliance now has a 180-day cure period to $35 million, making listing and capital access central.
Filed Sep 10, 2026 - FY2025 10-K risk factors47 risks4 new1 dropped8 reworded
Pluri faces significant going-concern doubts tied to its €50 million EIB loan repayment and upcoming milestones. The company is actively expanding plant-based verticals like Coffeesai and Kokomodo while managing Nasdaq listing compliance and U.S. tariff exposure.
Filed Sep 17, 2025 - FY2024 10-K risk factors44 risks
Pluri relies heavily on external capital raising and equity sales to fund its cash-constrained operations. The company faces significant regulatory, development, and commercialization hurdles across cell therapy, food tech, and agriculture. Nasdaq listing compliance is threatened due to a failure to meet stockholders equity requirements.
Filed Sep 18, 2024